Study guide
The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation
Certified Addictions Registered Nurse - Advanced Practice CARN-AP
Track your progress as you read
Finished sections get a check mark.
1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice
About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care
2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance
1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene
3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone
2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)
4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal
3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications
5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)
4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen
6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders
5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds
7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions
6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management
8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions
7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice
9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning
8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy
10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines
9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)
11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications
10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP
12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing
11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation
13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy
12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine
14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction
13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education
15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition
14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol
16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder
15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support
17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations
16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders
18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy
17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education
19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse
18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM
20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)
19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching
21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)
20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation
22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)
21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction
The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation
Key Takeaways Explain This Topic AI
The 2025 ANCB practice analysis rated "maintains practice grounded in neurobiology" third among all Area V activities, with a mean index of 10.15, making neurobiology a directly testable APRN competency rather than background theory.
Koob and Volkow's three-stage cycle maps binge/intoxication to the basal ganglia, withdrawal/negative affect to the extended amygdala, and preoccupation/anticipation to the prefrontal cortex.
Every major drug class converges on increased dopamine signaling in the nucleus accumbens, but by different routes: opioids and cannabis disinhibit VTA GABA interneurons, stimulants block or reverse the dopamine transporter, and alcohol and benzodiazepines act through GABA-A.
Allostasis explains why long-term users feel worse than baseline when abstinent: reward set point falls while CRF and dynorphin rise in the extended amygdala.
Incubation of craving means cue-induced craving intensifies over the first weeks to months of abstinence rather than declining, which is why relapse risk peaks after discharge rather than during withdrawal.
Last updated: September 2026
The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation
Quick Answer: Addiction is best modeled as a three-stage cycle (Koob and Volkow): binge/intoxication driven by dopamine release in the basal ganglia (nucleus accumbens, dorsal striatum); withdrawal/negative affect driven by recruitment of corticotropin-releasing factor (CRF) and dynorphin in the extended amygdala ; and preoccupation/anticipation driven by failure of prefrontal executive control. Every dependence-producing drug raises dopamine in the nucleus accumbens , but through class-specific mechanisms. Chronic use shifts the brain to an allostatic state with a lowered reward set point, and cue-induced craving incubates — intensifying over weeks of abstinence rather than fading.
The ANCB practice analysis placed “maintains practice grounded in neurobiology” third among 26 Area V activities (mean index 10.15, performed by 100 of 108 respondents). On the CARN-AP this is not background reading: it is the content that lets you answer “what should the APRN teach this family?” and “why did this patient relapse at week 6?”
1. The Three-Stage Cycle
Stage Dominant circuit Key neurochemistry Clinical face
Binge / Intoxication Basal ganglia — nucleus accumbens, dorsal striatum Phasic dopamine surge; opioid peptides; glutamatergic input from prefrontal cortex Euphoria, loss of control over amount, habit formation and progression from goal-directed to automatic use
Withdrawal / Negative affect Extended amygdala — central nucleus of the amygdala, bed nucleus of the stria terminalis, shell of the accumbens Reduced dopamine and reduced opioid peptide tone; increased CRF, dynorphin, norepinephrine, neuropeptide Y suppression Dysphoria, irritability, anhedonia, anxiety, sleep disruption; drug taken to relieve distress rather than to feel good
Preoccupation / Anticipation (“craving”) Prefrontal cortex — dorsolateral and ventromedial PFC, orbitofrontal cortex, anterior cingulate; insula Dysregulated glutamate projections to accumbens; impaired inhibitory control Rumination about use, impaired decision making, cue reactivity, planning around obtaining the substance
The cycle is not linear. A patient can loop between withdrawal and preoccupation for months, and each loop deepens the allostatic shift described below.
2. Convergence on Mesolimbic Dopamine
All classes end at the same place — more dopamine in the nucleus accumbens — but the route matters because it predicts withdrawal syndrome and medication choice.
Class Primary molecular action Route to accumbens dopamine
Opioids Mu-opioid receptor agonism Inhibit VTA GABA interneurons, disinhibiting dopamine neurons; also act directly in accumbens
Alcohol Positive modulation of GABA-A; NMDA antagonism Disinhibits VTA dopamine neurons; releases endogenous opioid peptides
Benzodiazepines / Z-drugs GABA-A positive allosteric modulation at the alpha-1 subunit Disinhibits VTA dopamine neurons
Cocaine Blocks the dopamine transporter (DAT), also NET and SERT Prevents reuptake, raising synaptic dopamine
Amphetamine / methamphetamine Reverses DAT and VMAT2 Forces non-vesicular dopamine efflux — a larger, longer surge than cocaine
Nicotine Agonist at alpha-4 beta-2 nicotinic acetylcholine receptors Directly excites VTA dopamine neurons and desensitizes inhibitory input
- Cannabis Partial agonism at presynaptic CB1 Suppresses GABA release onto VTA dopamine neurons
- Inhalants GABA-A potentiation, NMDA antagonism, membrane effects Disinhibits VTA dopamine neurons
Teaching point that lands with families: the fact that methamphetamine forces dopamine out of vesicles rather than merely blocking reuptake is why methamphetamine produces a larger and far more prolonged dopamine elevation than cocaine, and why anhedonia after methamphetamine cessation can persist for months.
3. Allostasis: Why Abstinence Initially Feels Worse Than Use
Homeostasis returns a system to its original set point. Allostasis achieves stability at a new set point, and that is what chronic substance exposure produces:
Repeated supraphysiologic dopamine surges trigger compensatory downregulation of D2 receptors and blunted dopamine release to natural rewards.
The anti-reward system in the extended amygdala is recruited: CRF, dynorphin acting at kappa-opioid receptors, and norepinephrine all rise.
The net result is a lowered hedonic set point . Food, sex, work and relationships produce less pleasure than before, while distress at baseline is higher.
This is the neurobiology behind protracted withdrawal (post-acute withdrawal): weeks to months of anhedonia, irritability, sleep disturbance and cue sensitivity after acute withdrawal has resolved. It is also the strongest argument the APRN can offer against the “just get through detox” model — acute withdrawal management does nothing to restore the reward set point, which is why detoxification alone increases overdose death risk.
4. Incubation of Craving
Animal and human data show that cue-induced craving increases over the first weeks to months of abstinence before slowly declining — a phenomenon called incubation of craving , linked to progressive accumulation of AMPA receptors in accumbens synapses.
Practical consequences the APRN should build into discharge planning:
The highest-risk window is often after the patient feels physically well, not during acute withdrawal.
Relapse-prevention intensity should be maintained or increased at weeks 4–12, exactly when patients and families assume the crisis has passed.
Long-acting medications (extended-release naltrexone, extended-release buprenorphine) have particular value across the incubation window, because they do not depend on daily decision making at the moment of peak craving.
5. Translating Neurobiology Into Language Patients Use
The practice analysis rated communication skills the single most important KSA. Neurobiology teaching fails when it becomes a lecture. Three framings that work:
“Your brain learned this faster than it learns anything else.” Explains salience and cue reactivity without implying weak will.
“The part of your brain that says stop is the part the drug damaged.” Explains impaired prefrontal control and reframes “why didn't you just stop?”
“Right now your baseline is lower than it used to be, and it comes back — but it takes months, not days.” Sets expectations for protracted withdrawal and preempts the week-6 relapse.